ESC 24: Hot Line & Late-breaking Science Video Collection
-
Part 3 | Session 4 SWEDEGRAFT: No-touch Vein Graft in CABG
-
Part 3 | Session 5 FINEARTS-HF: Finerenone HFmEF & HFpEF
-
Part 4 | Session 2 MATTERHORN: M-TEER vs Surgery in Heart Failure
-
Part 4 | Session 3 MRAs in Heart Failure
-
Part 4 | Session 4 FINE-HEART: Finerenone in HF & CKD
-
Part 4 | Session 5 STEEER-AF: Stroke Prevention & Rhythm Control Therapy
-
Part 4 | Session 6 NOTION-3: FFR Guided PCI in TAVI
-
Part 4 | Session 7 EPIC-CAD: Edoxaban vs Dual Antiplatelet Therapy in AF & CAD
-
Part 4 | Session 8 SENIOR RITA: Invasive Vs Conservative Strategy for Older Patients with MI
-
Part 4 | Session 9 EARTH-STEMI: Complete Vs Culprit-Only Revascularization in Older Patients
-
Part 4 | Session 10 SCOFF: Fasting vs. Non-Fasting: Impact on Cardiac Catheterization Outcomes
-
Part 4 | Session 11 GUARD-AF: Atrial Fibrillation Screening to Reduce Stroke in Elderly Individuals
-
Part 4 | Session 13 POPular PAUSE TAVI: Continuation or interruption of OAC During TAVI
-
Part 5 | Session 1 3 Trials That Will Change My Practice With Dr Muthiah Vaduganathan
-
Part 5 | Session 2 3 Trials That Will Change My Practice With Dr Michelle Kittleson
-
Part 6 | Session 1 New Guidelines for the Management of Atrial Fibrillation
-
Part 6 | Session 2 New Guidelines for the Management of Aortic Diseases
-
Part 1 | Session 1 ESC Congress 2024 Hot Line Wrap Up
-
Part 1 | Session 2 ESC Congress 2024 Hot Line Preview
-
Part 2 | Session 1 ESC Day 1 Wrap Up: New Guidelines, HELIOS-B, ABYSS & STOP-or-NOT
-
Part 2 | Session 2 ESC Day 2 Wrap-Up: NOTION-3, RESHAPE-HF2, TRI.Fr & More
-
Part 2 | Session 3 Day 3 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
Part 2 | Session 4 Day 4 Wrap-Up: OCCUPI, REC-CAGEFREE I, AEGIS-II & More
-
Part 3 | Session 1 AβYSS: Beta Blocker Interruption After Uncomplicated MI
-
Part 3 | Session 2 RHEIA: TAVR vs SAVR in Women with Severe AS
ESC Congress 2024 — OCEANIC-AF was halted early due to a lack of efficacy in 2023. Investigators shared details of the trial at ESC, comparing asundexian against apixaban in patients with atrial fibrillation at risk of stroke.
Host Dr Harriette Van Spall (McMaster University, Hamilton, Canada) sits down with primary investigator Dr Manesh R Patel (Duke University Health System, USA) to discuss the much-anticipated data from the OCEANIC-AF trial (NCT05643573; Bayer).
This multicentre, international, randomised, phase 3 study compared asundexian with apixaban in patients with atrial fibrillation and a high risk of stroke. Investigators enrolled 14,830 patients from 1,069 locations across various countries. The primary outcome measure was the time to first occurrence of a composite of stroke or systemic embolism.
Data revealed at ESC suggest that asundexian was inferior to apixaban (hazard ratio [HR] 3.79; 95% confidence interval [CI] 2.46-5.83) for stroke and systemic embolism prevention, but was associated with fewer major bleeding events (0.2% vs. 0.7%; HR 0.44; 95% CI 0.34-0.57).
Recorded on-site at ESC Congress 2024, London.
Editors: Jordan Rance and Mirjam Boros.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.
Support: This is an independent interview produced by Radcliffe Cardiology.
What's hot at the ESC Congress 2024?
Stay ahead of the curve with our faculty-led coverage of the European Society of Cardiology Congress in London. From groundbreaking trials to expert insights, we've got you covered.
- Watch our View From the Thoraxcenter series for practice-focused reviews of the most anticipated trials from interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen.
- For a deeper dive into key hot line clinical trial data and its applicability, host, Dr Harriette Van Spall meets with principal investigators in her Late-Breaker Discussion series.
- View a condensed summary of the crucial takeaways from each day in our Wrap-Up series led by Dr Mirvat Alasnag.
- Our short, bite-sized Expert Interviews with select faculty will focus on data, take-home messages for practice and the future of their field.
Get ready for a deep dive into the latest cardiology research. Our coverage of the ESC Congress is coming soon.
More from this programme
Part 1
View From the Thoraxcenter: What's Hot at ESC 24?
Part 2
Daily Wrap Ups with Dr Alasnag and Dr Al-Shaibi
Part 3
Hot-line Discussions with Dr Harriette Van Spall
Part 4
Expert Interviews
Part 5
Highlights
Part 6
Guidelines
Faculty Biographies

Manesh R Patel
Professor of Medicine / Chief, Division of Clinical Pharmacology / Chief, Division of Cardiology
Manesh Patel is the Chief of the Division of Cardiology and the Division of Clinical Pharmacology. His clinical interests include diagnostic and interventional coronary angiography, peripheral angiography and endovascular intervention. His is involved in several clinical trials involving patients with cardiovascular disease and in cardiac imaging. He is also the Chair of the American College of Cardiology Task Force for Appropriate Use Criteria for Cardiovascular Procedures and is Chair of the American Heart Association Diagnostic and Interventional Cath Committee.

Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.
She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.
Dr Van Spall is an Editorial Board…
Comments